Modus BioMedicine

Modus Therapeutics is a Swedish clinical-stage biotechnology company focused on developing its proprietary polysaccharide, sevuparin, for the treatment of diseases characterized by severe systemic inflammation and high unmet medical needs. The company's lead candidate, sevuparin, is a heparinoid designed to retain potent anti-inflammatory and anti-adhesive properties while exhibiting significantly reduced anti-coagulant activity, allowing for higher therapeutic dosing. Modus is currently evaluating sevuparin in clinical trials for indications including sepsis, severe malaria, and anemia associated with chronic kidney disease (CKD). By targeting the iron-regulating hormone hepcidin and modulating systemic inflammatory responses, the company aims to create a paradigm shift in the management of acute and chronic inflammatory disorders.